格隆汇4月25日丨康臣药业(01681.HK)发布公告,公司已收到中国国家药品监督管理局签发的有关SK-09片的《药物临床试验批准通知书》。SK-09片为一类化学新药。根据披露,足细胞损伤相关肾脏疾病是一类以肾小球足细胞损伤为主要病理改变的肾脏疾病,包括糖尿病肾病、局灶节段性肾小球硬化、微小病变肾病等。患者常因得不到及时有效的治疗,最终进展为终末期肾病(ESRD),对患者本人、家庭及社会医疗造成...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.